Core Insights - Changchun High-tech announced a collaboration with Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China, specifically targeting house dust mite (HDM) allergens [1] - The agreement includes an initial payment of €32.7 million, with additional milestone payments totaling €40 million for regulatory approval and up to €105 million based on sales performance in China [1] - The global allergy immunotherapy market is projected to reach $3.2 billion by 2030, with a compound annual growth rate (CAGR) of 9.5%, highlighting significant growth potential in this sector [1] Company Summary - JinSai Pharmaceutical, a subsidiary of Changchun High-tech, will lead the collaboration and has secured exclusive rights to three products developed by ALK for the Chinese market [1] - The partnership aims to address the unmet clinical needs in China, where the number of patients receiving desensitization therapy is currently below 1 million, despite having the largest population of house dust mite allergy sufferers globally [1] Industry Summary - The allergy immunotherapy market in China is underdeveloped and lacks innovative products, presenting a substantial opportunity for growth [1] - The collaboration is expected to enhance the availability of effective treatments for a significant patient population suffering from dust mite allergies in China [1]

Core Insights - ALK presented significant advancements in anaphylaxis and pediatric allergy at the EAACI 2025 congress, highlighting innovations in treatment options and clinical evidence [1][4] Group 1: Innovations in Anaphylaxis Treatment - The EURneffy nasal adrenaline spray was introduced as a new treatment for anaphylaxis, supported by real-world data demonstrating its effectiveness in acute cases [2] - The nasal spray's pharmacological response is comparable to that of intramuscular adrenaline injections in patients with allergic rhinitis [2] Group 2: Immunotherapy Developments for Children - ALK showcased clinical evidence for sublingual allergy immunotherapy tablets aimed at children with respiratory allergies, indicating a transformative potential for allergy care [3] - Real-life data supports the long-term benefits of allergy immunotherapy in managing both upper and lower airway diseases in children [3] - Preliminary findings from the ALLIANCE clinical trial suggest that the peanut SLIT-tablet may be a well-tolerated treatment option for children with peanut allergies [3]